Nivolumab for the treatment of unresectable pleural mesothelioma

Katsuyuki Hotta, Nobukazu Fujimoto, Toshiyuki Kozuki, Keisuke Aoe, Katsuyuki Kiura

Research output: Contribution to journalArticle

Abstract

Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. Nivolumab, an anti-programmed cell death (PD)-1 agent, was one of the first drugs used and is representative of available ICIs. Areas covered: This review discusses previous relevant reports and current ongoing trials of nivolumab. The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs. Particularly, nivolumab monotherapy yielded promising efficacy with an objective response rate of 29% and median overall survival of 17.3 months in salvage settings in the single-arm, Japanese phase 2 trial (MERIT). Notably, the study led to Japanese approval of nivolumab for unresectable recurrent MPM. Several trials with monotherapy or cotherapy with nivolumab have commenced, including randomized trials of nivolumab monotherapy vs. placebo in the salvage setting, and cotherapy with nivolumab and ipilimumab vs. the platinum doublet in the frontline setting. Expert opinion: Nivolumab seems like a reasonable option for unresectable, relapsed MPM despite the lack of randomized trial data. Ongoing pivotal trials will confirm its efficacy.

Original languageEnglish
JournalExpert Opinion on Biological Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Mesothelioma
Salvaging
Therapeutics
Platinum
nivolumab
Chemotherapy
Expert Testimony
Cell death
Cell Death
Placebos
Safety
Drug Therapy

Keywords

  • CTLA-4
  • immune checkpoint inhibitor
  • Mesothelioma
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Nivolumab for the treatment of unresectable pleural mesothelioma. / Hotta, Katsuyuki; Fujimoto, Nobukazu; Kozuki, Toshiyuki; Aoe, Keisuke; Kiura, Katsuyuki.

In: Expert Opinion on Biological Therapy, 01.01.2019.

Research output: Contribution to journalArticle

@article{c64f13851f2b44f298b148d05c5afee8,
title = "Nivolumab for the treatment of unresectable pleural mesothelioma",
abstract = "Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. Nivolumab, an anti-programmed cell death (PD)-1 agent, was one of the first drugs used and is representative of available ICIs. Areas covered: This review discusses previous relevant reports and current ongoing trials of nivolumab. The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs. Particularly, nivolumab monotherapy yielded promising efficacy with an objective response rate of 29{\%} and median overall survival of 17.3 months in salvage settings in the single-arm, Japanese phase 2 trial (MERIT). Notably, the study led to Japanese approval of nivolumab for unresectable recurrent MPM. Several trials with monotherapy or cotherapy with nivolumab have commenced, including randomized trials of nivolumab monotherapy vs. placebo in the salvage setting, and cotherapy with nivolumab and ipilimumab vs. the platinum doublet in the frontline setting. Expert opinion: Nivolumab seems like a reasonable option for unresectable, relapsed MPM despite the lack of randomized trial data. Ongoing pivotal trials will confirm its efficacy.",
keywords = "CTLA-4, immune checkpoint inhibitor, Mesothelioma, PD-1, PD-L1",
author = "Katsuyuki Hotta and Nobukazu Fujimoto and Toshiyuki Kozuki and Keisuke Aoe and Katsuyuki Kiura",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/14712598.2020.1703945",
language = "English",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Nivolumab for the treatment of unresectable pleural mesothelioma

AU - Hotta, Katsuyuki

AU - Fujimoto, Nobukazu

AU - Kozuki, Toshiyuki

AU - Aoe, Keisuke

AU - Kiura, Katsuyuki

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. Nivolumab, an anti-programmed cell death (PD)-1 agent, was one of the first drugs used and is representative of available ICIs. Areas covered: This review discusses previous relevant reports and current ongoing trials of nivolumab. The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs. Particularly, nivolumab monotherapy yielded promising efficacy with an objective response rate of 29% and median overall survival of 17.3 months in salvage settings in the single-arm, Japanese phase 2 trial (MERIT). Notably, the study led to Japanese approval of nivolumab for unresectable recurrent MPM. Several trials with monotherapy or cotherapy with nivolumab have commenced, including randomized trials of nivolumab monotherapy vs. placebo in the salvage setting, and cotherapy with nivolumab and ipilimumab vs. the platinum doublet in the frontline setting. Expert opinion: Nivolumab seems like a reasonable option for unresectable, relapsed MPM despite the lack of randomized trial data. Ongoing pivotal trials will confirm its efficacy.

AB - Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this disease. Nivolumab, an anti-programmed cell death (PD)-1 agent, was one of the first drugs used and is representative of available ICIs. Areas covered: This review discusses previous relevant reports and current ongoing trials of nivolumab. The efficacy and safety of nivolumab have been investigated mostly in second-line or later treatment settings as both monotherapy and in combination with other ICIs. Particularly, nivolumab monotherapy yielded promising efficacy with an objective response rate of 29% and median overall survival of 17.3 months in salvage settings in the single-arm, Japanese phase 2 trial (MERIT). Notably, the study led to Japanese approval of nivolumab for unresectable recurrent MPM. Several trials with monotherapy or cotherapy with nivolumab have commenced, including randomized trials of nivolumab monotherapy vs. placebo in the salvage setting, and cotherapy with nivolumab and ipilimumab vs. the platinum doublet in the frontline setting. Expert opinion: Nivolumab seems like a reasonable option for unresectable, relapsed MPM despite the lack of randomized trial data. Ongoing pivotal trials will confirm its efficacy.

KW - CTLA-4

KW - immune checkpoint inhibitor

KW - Mesothelioma

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85076821749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076821749&partnerID=8YFLogxK

U2 - 10.1080/14712598.2020.1703945

DO - 10.1080/14712598.2020.1703945

M3 - Article

C2 - 31825692

AN - SCOPUS:85076821749

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

ER -